Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors

Park, Hyun-Jung; Park, Hyerin; Baek, Ji-Yeon; Moon, Hyuk; Ro, Simon Weonsang

doi:10.3390/biology11040585

Cited by 8 publications

(4 citation statements)

References 179 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The receptor tyrosine kinases (RTKs) are the pivotal factors in regulating physiological function of normal cell. Dysregulation of certain RTKs, especially insulin-like growth factor (IGF)-1 receptor (IGF-1R), epidermal growth factor receptor (EGFR), EGFR type 2 (HER2), and vascular endothelial growth factor (VEGF) receptor (VEGFR), are largely related to the acquisition of malignant hallmarks of tumor, as a result of which RTKs have become the most practical molecular targets for HCC therapy ( Shimizu et al, 2011a ; Park et al, 2022 ). Increasing evidence has proved EGCG can suppress the abnormal activation of multiple RTKs and their downstream signaling molecules in HCC.…”

Section: The Roles Of Egcg In Chemoprevention and Anti-cancer ...mentioning

confidence: 99%

The potential of epigallocatechin gallate in the chemoprevention and therapy of hepatocellular carcinoma

Cao

Cui

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), one of the most notorious malignancies globally, has a high fatality and poor prognosis. Though remarkable breakthroughs have been made in the therapeutic strategies recently, the overall survival of HCC remains unsatisfactory. Consequently, the therapy of HCC remains a great challenge. Epigallocatechin gallate (EGCG), a natural polyphenol extracted from the leaves of the tea bush, has been extensively investigated for its antitumor effects. In this review, we summarize the previous literature to elucidate the roles of EGCG in the chemoprophylaxis and therapy of HCC. Accumulating evidence has confirmed EGCG prevents and inhibits the hepatic tumorigenesis and progression through multiple biological mechanisms, mainly involving hepatitis virus infection, oxidative stress, proliferation, invasion, migration, angiogenesis, apoptosis, autophagy, and tumor metabolism. Furthermore, EGCG enhances the efficacy and sensitivity of chemotherapy, radiotherapy, and targeted therapy in HCC. In conclusion, preclinical studies have confirmed the potential of EGCG for chemoprevention and therapy of HCC under multifarious experimental models and conditions. Nevertheless, there is an urgent need to explore the safety and efficacy of EGCG in the clinical practice of HCC.

show abstract

Section: The Roles Of Egcg In Chemoprevention and Anti-cancer ...mentioning

confidence: 99%

The potential of epigallocatechin gallate in the chemoprevention and therapy of hepatocellular carcinoma

Cao

Cui

et al. 2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Stabilization of the β-catenin protein destruction complex allows inactivation of the Wnt pathway. Tankyrase (TNKS) is an activator of the Wnt/β-catenin cascade since it degrades the negative regulators of β-catenin, AXIN1 and AXIN2, through proteasomal degradation mediated by ubiquitin [ 43 , 152 ]. TNKS inhibitors negatively regulate Wnt signaling by stabilizing AXIN and antagonizing the Wnt/β-catenin pathway.…”

Section: Therapeutic Perspectivesmentioning

confidence: 99%

Infectious Agents Induce Wnt/β-Catenin Pathway Deregulation in Primary Liver Cancers

et al. 2023

View full text Add to dashboard Cite

Interaction between infectious agents and liver tissue, as well as repeated and extreme biological events beyond adaptive capacities, may result in pathological conditions predisposing people to development of primary liver cancers (PLCs). In adults, PLCs mainly comprise hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA). Various infectious agents in the hepatic microenvironment can destabilize normal liver cell functions by modulating the Wnt/β-catenin pathway components. Among them, hepatotropic viruses B, C, and D are involved in Wnt/β-catenin signaling dysregulation. Other microbial agents, including oncogenic viruses such as Epstein–Barr virus (EBV) and human papilloma virus (HPV), bacteria, e.g., Mycoplasma hyorhinis and Salmonella Typhi, the protozoan parasite Toxoplasma gondii, the fungus Aspergillus flavus, and liver flukes such as Clonorchissinensis or Opisthorchis viverrini, may induce malignant transformation in hepatocytes or in target cells of the biliary tract through aberrant Wnt signaling activation. This review focuses on new insights into infectious agents implicated in the deregulation of Wnt signaling and PLC development. Since the Wnt/β-catenin pathway is a driver of cancer following viral and bacterial infections, molecules inhibiting the complex axis of Wnt signaling could represent novel therapeutic approaches in PLC treatment.

show abstract

“…PD-L1 binds to its PD1 receptor and inhibits T-cell activation (42). Several PD-1 and PD-L1 related antibodies have been approved for HCC, however, the group of responders and the clinical benefit are limited (43)(44)(45).…”

Section: Circrnas Up-regulating Transmembrane Receptorsmentioning

confidence: 99%

Hepatocellular Carcinoma: Up-regulated Circular RNAs Which Mediate Efficacy in PreclinicalIn VivoModels

WEIDLE,

NOPORA

2023

Cancer Genomics Proteomics

View full text Add to dashboard Cite

show abstract

Target Therapy for Hepatocellular Carcinoma: Beyond Receptor Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors

Cited by 8 publications

References 179 publications

The potential of epigallocatechin gallate in the chemoprevention and therapy of hepatocellular carcinoma

The potential of epigallocatechin gallate in the chemoprevention and therapy of hepatocellular carcinoma

Infectious Agents Induce Wnt/β-Catenin Pathway Deregulation in Primary Liver Cancers

Hepatocellular Carcinoma: Up-regulated Circular RNAs Which Mediate Efficacy in PreclinicalIn VivoModels

Contact Info

Product

Resources

About